CV Therapeutics, Inc., a biopharmaceutical company, focuses on applying molecular cardiology to the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its approved product, Ranexa (ranolazine extended-release tablets) is indicated for the treatment of chronic angina. The company also develops Ranexa, which is in Phase III clinical development stage for the treatment of acute coronary syndrome. In addition, it has other clinical and preclinical drug development candidates and programs, including Regadenoson, which is in Phase III clinical development stage for use as a pharmacologic stress agent in myocardial perfusion...